Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain.We conducted an active-comparator-controlled, double-blind,...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2025
|
| Sorozat: | NEW ENGLAND JOURNAL OF MEDICINE
393 No. 24 |
| Tárgyszavak: | |
| doi: | 10.1056/NEJMoa2505928 |
| mtmt: | 36504479 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/38555 |